The Latest Cardiac and Vascular News
VEMERIX analysis finds the single-use consumable, not the capital laser console, is the value engine in the USD 1.4–1.6 billion varicose-vein device market — with Asia-Pacific growing fastest at up to 8.4% CAGR. WEIHAI, China, June 29, 2026 /PRNewswire/ — VEMERIX, the international…
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today that it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2026 Russell indexes reconstitution, effective after the U.S. market close on June 26, 2026. The Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place until the next semi-annual reconstitution, means automatic inclusion in small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell indexes are part of FTSE Russell, a leading global index provider. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.2 trillion in assets are benchmarked against Russell’s U.S. indexes. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website here. About Orchestra BioMedOrchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and a global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn. About FTSE RussellFTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $12.2 trillion in assets are benchmarked against Russell’s U.S. indexes. For over 30 years, leading asset owners, asset managers, ETF providers, and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth, and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com. References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. Investor Contact:Silas NewcombOrchestra BioMedSnewcomb@orchestrabiomed.com Media Contact:Nina PremuticoOrchestra BioMednpremutico@orchestrabiomed.com
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) — GuideAI Health Corp. (“GuideAI” or the “Company”) (Cboe CA: GDAI) is pleased to report that the Company has received final approval to list its common shares (the “Shares”) on Cboe Canada Inc. (“Cboe Canada”). The Company anticipates that the Shares will begin trading at the market open on the 29th of June 2026. Once listed, the Shares are expected to trade under the ticker symbol “GDAI,” with an ISIN of CA40173G1019 and a CUSIP of 40173G101. Investors can trade shares of GDAI through their usual investment channels, including discount brokerages and full-service dealers. “Going public represents an important milestone for GuideAI as we scale our platform and expand access to advanced diagnostic technology,” said Raj Shah, Chief Executive Officer of GuideAI Health Corp. “We are excited to join the Cboe Canada community and look forward to advancing our mission of improving outcomes for patients, clinicians, and shareholders alike.” “We are pleased to welcome GuideAI to Cboe Canada,” said CEO, Joacim Wiklander. “Their work at the intersection of artificial intelligence and cardiovascular health represents exactly the kind of innovative, high-growth company that Canadian public markets should be supporting. We look forward to their continued growth as a publicly listed company.” About GuideAI Health Corp. GuideAI Health Corp. is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease. By surfacing disease earlier, GuideAI aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care. About Cboe Canada Cboe Canada is Canada’s senior stock exchange providing a best-in-class listing experience for issuers that are shaping the economies of tomorrow. Fully operational since 2015, Cboe Canada lists companies and investment products seeking a robust and internationally recognized platform that enables investor trust, quality liquidity, and broad awareness including unfettered access to market data. On Behalf of the Board of Directors: Raj Shah CEO Contact: Phone: (416) 309-3583Email: info@guideaihealth.com www.guideaihealth.com/ Cautionary Note Regarding Forward-Looking Statements This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding the anticipated listing and commencement of trading of the Shares on Cboe Canada, the expected trading symbol, and the Company’s business plans and objectives. These statements are based on assumptions and expectations that management considers reasonable as of the date of this release, including that Cboe Canada will grant final listing approval and that all listing conditions will be satisfied. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, delays in or failure to obtain final Cboe Canada approval, changes in market conditions, regulatory developments, and other risks described in the Company’s public disclosure documents available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Cboe Canada has not reviewed, approved, or disapproved the contents of this news release, and does not accept responsibility for the adequacy or accuracy of this release.
Marks a major milestone in expanding access to this next-generation intravascular imaging technology, helping physicians make more informed decisions across a wide range of coronary interventions Addresses the need to balance the deep vessel visualization of IVUS with the high-resolution…
Company has received $1.75 million in total under the program, including a $1.25 million payment triggered by the Company’s U.S. FDA clearance, to support the commercial launch of its hybrid IVUS-OCT imaging systemTORONTO, June 29, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (“Conavi” or the “Company”) (TSXV: CNVI; OTCQB: CNVIF), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it has received a milestone payment of $1.25 million from the Province of Ontario through the Life Sciences Scale-Up Fund (“LSSUF”). The milestone payment was triggered by Conavi’s achievement of U.S. FDA 510(k) clearance for its hybrid imaging system — the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. “We are grateful to the Province of Ontario, the Ministry of Economic Development, Job Creation and Trade, and Minister Vic Fedeli for their continued support of Conavi,” said Tom Looby, Chief Executive Officer of Conavi Medical. “Having received $1.75 million under the program, we are pleased that this milestone payment recognizes our achievement of FDA clearance. This funding supports the commercialization of our hybrid imaging system as we build our presence in the U.S. market following FDA clearance.” As previously announced, Conavi entered into an agreement with the Province of Ontario in October 2025 under the LSSUF program, which provides support to help Ontario-based life sciences companies scale their operations and commercialize innovative technologies. Under the agreement, Conavi is eligible to receive up to $2.5 million in funding based on the achievement of specified milestones. Following receipt of the $1.25 million milestone payment, the Company has now received a total of $1.75 million under the program to date. The Company remains eligible to receive additional funding under the program, subject to the achievement of future milestones. The Company will use the proceeds received under the LSSUF program to support commercialization initiatives, manufacturing scale-up activities and other eligible project costs associated with the launch of its hybrid imaging system. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/. Notice on forward-looking statementsThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. CONTACT:Chief Financial Officer: Mark Quick, 416-483-0100Investors: Christina Cameron, 416-483-0100 ext.121, IR@conavi.com
NEW YORK–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company’s leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
Independent DMC recommends continued conduct of the MUSIC-HFpEF study without protocol modification following scheduled review of accumulated clinical data; randomized HFrEF Phase 2 study also reviewed with no safety concerns requiring changes to study conductBOSTON, June 25, 2026 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biotechnology company developing disease-modifying gene therapies for cardiovascular disease, today announced that the independent Data Monitoring Committee (DMC) has completed its scheduled review of the Company’s ongoing MUSIC-HFpEF clinical trial evaluating SRD-002, Medera’s investigational AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction (HFpEF). Following review of accumulated clinical data, the independent DMC recommended that the MUSIC-HFpEF study continue without protocol modification. The committee identified no safety concerns requiring changes to study conduct, supporting continued advancement of Medera’s lead clinical program as the Company prepares for discussions with the U.S. Food and Drug Administration (FDA) regarding the next randomized stage of development. The DMC recommendation followed review of accumulated safety and clinical data, including long-term follow-up from both dose cohorts. “We are very encouraged by the outcome of this independent DMC review,” said Ronald Li, PhD, Chief Executive Officer and Founder of Medera. “Independent review by the DMC represents an important milestone for our lead HFpEF program. The review reflected the safety data collected to date and consistency in the physiological and clinical observations across hemodynamic and functional measures. We are particularly encouraged that an independent committee of experienced heart failure specialists and clinical trial experts recommended continued conduct of the study without modification. We believe this outcome further supports the favorable safety profile observed to date and provides additional confidence as we prepare for the next stage of randomized study.” SRD-002 is Medera’s investigational AAV1/SERCA2a gene therapy designed to restore SERCA2a expression and normalize impaired calcium handling within cardiomyocytes, a fundamental biological abnormality underlying HFpEF. Unlike currently approved therapies that primarily improve symptoms or reduce cardiovascular risk, SRD-002 is being developed as a potential disease-modifying therapy targeting the underlying myocardial pathobiology responsible for impaired cardiac relaxation and elevated cardiac filling pressures. The program utilizes Medera’s proprietary targeted intracoronary delivery platform, enabling localized cardiac gene transfer through a minimally invasive catheter-based outpatient procedure while minimizing systemic vector exposure and substantially reducing vector dose requirements compared with conventional systemic intravenous administration. As of the latest DMC review, all ten patients have been successfully treated across two dose cohorts (Cohort A: 3.0 × 10¹³ vg; Cohort B: 4.5 × 10¹³ vg). All patients in Cohort A have completed 12-month follow-up, while patients in Cohort B continue scheduled long-term follow-up. The DMC reviewed comprehensive safety information, including adverse events, laboratory assessments, hepatic function, immune monitoring, and cardiovascular safety data. No gene therapy-related serious adverse events have been reported across the HFpEF clinical program to date. As previously reported at the American Heart Association Scientific Sessions 2025 as a Late-Breaking Clinical Trial Presentation, our Cohort A patients have shown improvements in New York Heart Association (NYHA) functional class, Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, and hemodynamic parameters, including pulmonary capillary wedge pressure (PCWP), a direct measure of cardiac filling pressure and a central physiological hallmark of HFpEF, at rest and during exercise. The company expects to report 12-month data from Cohort B patients in the last quarter of 2026. “HFpEF remains one of the largest unmet needs in cardiovascular medicine and one of the most challenging diseases to study because of its marked biological and clinical heterogeneity,” added Dr. Li. “We believe objective physiological measurements provide a rigorous framework for assessing therapeutic effects in this setting. This independent DMC recommendation represents an important clinical and regulatory de-risking milestone as we continue preparing for randomized development and future FDA interactions.” The independent DMC also completed its scheduled review of Medera’s MUSIC-HFrEF Phase 1/2a clinical trial data, with no safety concerns identified. The randomized MUSIC-HFrEF Phase 2b trial is currently ongoing. “The independent DMC reviews across both our HFpEF and randomized HFrEF programs provide encouraging support for the safety profile observed to date with our cardiovascular gene therapy platform,” said Roger J. Hajjar, MD, President and Chief Medical Officer of Medera. “We remain focused on completing long-term follow-up, generating robust clinical evidence, and advancing both programs through their next stages of clinical and regulatory development.” Medera expects to provide additional updates regarding its HFpEF and HFrEF clinical programs, including future data presentations, regulatory interactions, and development milestones, as they become available. About Heart Failure with Preserved Ejection Fraction (HFpEF) Heart failure affects more than 64 million people worldwide, with HFpEF accounting for approximately half of all heart failure cases. Patients with HFpEF experience morbidity and mortality comparable to those with heart failure with reduced ejection fraction (HFrEF). Despite its growing prevalence, currently approved therapies primarily improve symptoms and reduce cardiovascular risk rather than directly targeting the underlying myocardial abnormalities responsible for the disease. Consequently, HFpEF remains one of the largest unmet needs in cardiovascular medicine and an area of active therapeutic development. About Medera Inc. Medera is a clinical-stage biotechnology company developing next-generation gene therapies for cardiovascular and other serious diseases. Its pipeline includes multiple AAV-based gene therapy programs targeting heart failure and related cardiovascular disorders. The Company operates through two complementary business units: Novoheart, which provides advanced human-specific cardiac disease modeling and drug discovery platforms, and Sardocor, which leads clinical development of Medera’s gene therapy pipeline. Together, these capabilities create an integrated translational platform spanning discovery, preclinical validation, manufacturing, and clinical development. For more information, please visit www.medera.bio. Forward-Looking Statements This press release contains forward-looking statements regarding Medera’s investigational products, anticipated regulatory interactions, clinical development plans, future clinical data, and potential therapeutic benefits. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Contacts Ally StubinPublic RelationsICR HealthcareAlly.stubin@icrhealthcare.com646.667.1861 Stephanie CarringtonInvestor RelationsICR HealthcareStephanie.carrington@icrhealthcare.com646.277.1282
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
TEMPE, Ariz., June 25, 2026 (GLOBE NEWSWIRE) — Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational Nectero EAST® System. The study met safety endpoints, and AAA growth rates were significantly lower than expected through two years post-treatment. At the 2026 Vascular Annual Meeting (VAM) held in Boston last week, the impact of PGG treatment on proximal neck dynamics was presented by Dr. Matthew Eagleton, Chief, Mass General Brigham Vascular and Endovascular Surgery.
IRVINE, Calif.–(BUSINESS WIRE)–Johnson & Johnson advances cardiac ablation technology in Europe with availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
